SS-31
Mitochondria-targeted tetrapeptide investigated for potential protective effects in disorders involving mitochondrial dysfunction.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
SS-31 (also known as elamipretide in some literature) is a mitochondria- targeted tetrapeptide studied for potential protective effects in conditions characterized by mitochondrial dysfunction.
Mechanism of action
SS-31 is designed to localize to the inner mitochondrial membrane and interact with cardiolipin, with the goal of stabilizing mitochondrial structure and improving bioenergetics under stress.
Indications and use context
Clinical programs have explored SS-31 in cardiomyopathies, mitochondrial myopathies, and other disorders, but approved uses, if any, are product- and region-specific.
Outside formal trials and labeled indications, use should be considered experimental.
Safety and side effects
Safety information comes from early-phase clinical trials and preclinical studies.
Reported adverse effects vary by study and indication; up-to-date product labeling and trial reports are the primary reference for detailed safety information.
Pharmacology and dosing considerations
SS-31 (Elamipretide) targets the mitochondrial membrane.
Route: Subcutaneous injection.
Protocol structure and dosage:- Dosage: Clinical trials have used doses around 40 mg daily.
- Frequency: Once daily.
- Note: High doses (mg range) are typical compared to potent hormone peptides (mcg range).
This information is derived from clinical trials for mitochondrial myopathy.
Formulations and combinations
Catalog entries may list SS-31 as an injectable peptide and conceptually group it with other agents targeting mitochondrial health.
Research and evidence snapshot
Research includes preclinical models and human trials evaluating functional endpoints and quality-of-life measures. Results are mixed and indication- specific.
Frequently asked questions
Future FAQs may explore how SS-31 and related agents fit into the evolving landscape of mitochondrial therapies and how clinicians interpret emerging data. Answers will remain educational and non-prescriptive.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.